Vimarsana
Biggest News Aggregation in the World

Page 4 - Expansion Phase News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Expansion Phase. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Expansion Phase Today - Breaking & Trending Today

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients - Vimarsana News

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

Issued by the Japanese Patent Office A New Protection Covering Tedopi Until 2037 Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today announced that

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles - Vimarsana News

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Briones hopes more PH schools will offer face-to-face classes by January 2022 - Vimarsana News

Briones hopes more PH schools will offer face-to-face classes by January 2022

With the planned expansion of limited face-to-face classes next year, the Department of Education (DepEd) expressed optimism that more schools will be allowed to reopen their doors to their students. In a statement issued Tuesday, Dec. 28, DepEd said that Education Secretary Leonor Magtolis Brione

Source: mb.com.ph
OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer - Vimarsana News

OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer

In Addition, Three Senior Executives Will Reinforce the Company’s Drug Development Engine ...

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia - Vimarsana News

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

At the 2021 American Society of Hematology (ASH) Annual Meeting Regulatory News: OSE Immunotherapeutics SA (Paris:OSE) (ISIN: FR0012127173; Mnemo: OSE) presented the first preclinical data on